AKR1C3 suppresses ferroptosis in hepatocellular carcinoma through regulation of YAP/SLC7A11 signaling pathway
Molecular Carcinogenesis · 2023-06 · 62 (6) · 833-844
DOI: 10.1002/mc.23527 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Carcinogenesis, online erschienen am 15.03.2023. Verfasst von Jinsi Chen und 6 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Sha…. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Ferroptosis, Liver Neoplasms. Die Arbeit wurde bisher 53-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Natural Science Foundation of Shanghai, National Natural Science Foundation of China.
Abstract (Originalsprache)
AKR1C3 is frequently overexpressed and it is a validated therapeutic target in various tumors including hepatocellular carcinoma (HCC). Our previous study showed that AKR1C3 facilitated HCC proliferation and metastasis by forming a positive feedback loop of AKR1C3‐NF‐κB‐STAT3. Ferroptosis is a form of iron‐dependent cell death driven by iron‐dependent accumulation of lipid reactive oxygen species and plays an important role in tumor suppression. However, little is known about the role of AKR1C3 in ferroptosis susceptibility. In this study, we found that knockdown of AKR1C3 potently enhanced the sensitivity of HCC cells to ferroptosis inducers both in vitro and in vivo. Overexpression of AKR1C3 protected against ferroptosis in HCC cells. Mechanistically, AKR1C3 regulated ferroptosis through YAP/SLC7A11 signaling in HCC. AKR1C3 knockdown led to a decrease in YAP nuclear translocation, resulted in the inhibition of cystine transporter SLC7A11, and a subsequent increase in the intracellular levels of ferrous iron and ultimately ferroptosis. Moreover, we found that the combination of AKR1C3 and SLC7A11 was a strong predictor of poor prognosis in HCC. Collectively, these findings identify a novel role of AKR1C3 in ferroptosis, and highlighting a candidate therapeutic target to potentially improve the effect of ferroptosis‐based antitumor therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
ORCID-Profile: Hua Tian
Förderung
- Natural Science Foundation of Shanghai
- National Natural Science Foundation of China
Zitieren
APA
Chen, J., Zhang, J., Tian, W., Ge, C., Su, Y., Li, J., & Tian, H. (2023). AKR1C3 suppresses ferroptosis in hepatocellular carcinoma through regulation of YAP/SLC7A11 signaling pathway. Molecular Carcinogenesis, 62(6), 833-844. https://doi.org/10.1002/mc.23527
Vancouver
Chen J, Zhang J, Tian W, Ge C, Su Y, Li J, et al. AKR1C3 suppresses ferroptosis in hepatocellular carcinoma through regulation of YAP/SLC7A11 signaling pathway. Molecular Carcinogenesis. 2023;62(6):833-844. doi:10.1002/mc.23527
BibTeX
@article{Chen2023,
author = {Chen, Jinsi and Zhang, Jia and Tian, Wei and Ge, Chao and Su, Yuting and Li, Jinjun and Tian, Hua},
title = {AKR1C3 suppresses ferroptosis in hepatocellular carcinoma through regulation of YAP/SLC7A11 signaling pathway},
journal = {Molecular Carcinogenesis},
year = {2023},
volume = {62},
number = {6},
pages = {833--844},
doi = {10.1002/mc.23527}
}
EUVIMED